Truist Securities Maintains Buy on Axogen, Lowers Price Target to $53
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and lowers the price target from $60 to $53.
Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and lowers the price target from $60 to $53.